Ferozsons Laboratories Approves Crucial Related Party Transactions

Karachi: Ferozsons Laboratories Limited, a prominent player in the pharmaceutical industry, has announced significant updates to its related party transactions during its upcoming Annual General Meeting, slated for later this month. The company has moved the approval of these transactions to a special business section following a recent amendment to the meeting’s agenda.

In a recent addendum dated October 7, 2024, the company specified changes to Clause 5 of the original notice for the Annual General Meeting. According to information available from the Pakistan Stock Exchange (PSX), the new arrangement places the approval of related party transactions right after Clause 6, highlighting the strategic importance of these transactions to the company’s operations.

The Board of Directors, following recommendations from the Audit Committee as per the 2019 Listed Companies (Code of Corporate Governance) Regulations, has approved these transactions. The transactions, primarily involving subsidiary companies, are detailed in note no. 41 of the unconsolidated financial statements for 2024.

Notable transactions from 2024 include sales and purchases of medicines amounting to PKR 696.97 million and PKR 825,204 respectively, with corresponding payments aligning with these figures. The company also reported significant expenses incurred on behalf of BF Biosciences Limited, totaling PKR 108.18 million, a notable increase from the previous year’s PKR 46.15 million. These financial interactions underscore the extensive financial and operational interdependencies within Ferozsons’ corporate family, which also includes an 80% ownership in BF Biosciences Limited and a 98% stake in the subsidiary partnership firm, Farmacia.

The transactions for approval also cover a variety of other financial activities, including short-term borrowings, corporate guarantees, and employee-related payments such as contributions towards provident funds and remunerations, reflecting the comprehensive scope of the company’s internal financial engagements.

The Annual General Meeting will also see shareholder votes on other critical aspects of the company’s governance and future strategy, ensuring that Ferozsons Laboratories remains compliant with regulatory requirements and aligned with best corporate practices.

The post Ferozsons Laboratories Approves Crucial Related Party Transactions appeared first on .